Editor: What To Know
- taxpayer bearing virtually the entire $700 million burden spent so far to develop a cure and a vaccine to this dire threat to public health, no drug company should benefit by getting an exclusive monopoly license to charge whatever they want for it,” said Michael Weinstein, president of AHF.
- “In fact, the lack of serious investment from these greedy companies gives lie to their empty talking points that they need to charge obscene prices and rake in sky-high profits to come up with the next cure.
- Weinstein concluded, “While AHF thanks these members of Congress for this statement, the drug industry has been thanking the generosity of the U.
AIDS Healthcare Foundation (AHF) strongly agrees with this reasonable request as stated in the letter sent to President Trump on February 20.
“With the U.S. taxpayer bearing virtually the entire $700 million burden spent so far to develop a cure and a vaccine to this dire threat to public health, no drug company should benefit by getting an exclusive monopoly license to charge whatever they want for it,” said Michael Weinstein, president of AHF. “In fact, the lack of serious investment from these greedy companies gives lie to their empty talking points that they need to charge obscene prices and rake in sky-high profits to come up with the next cure.”
Weinstein concluded, “While AHF thanks these members of Congress for this statement, the drug industry has been thanking the generosity of the U.S. taxpayer by charging them the highest prices for medicine in the world. Those drug companies spend more on advertising, marketing, stock buybacks and CEO salaries than they do on research and development is well known.”
